Effectiveness and safety of a prevention-of-flare-progression strategy with pimecrolimus cream 1% in the management of paediatric atopic dermatitis

Journal of the European Academy of Dermatology and Venereology

Volumn 22, Issue 11, 2008, Pages 1290-1301

  Sigurgeirsson, B ^a,e   Ho, V ^b   Ferrandiz C ^c   Andriano, K ^d   Grinienko, A ^d   Jimenez, P ^d  

^a UNIVERSITY OF ICELAND   (Iceland)

^b Skin Care Center   (Canada)

^c HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^d NOVARTIS PHARMA AG   (Switzerland)

^e Hudlaeknastodin Ehf ^*  (Iceland)

Author keywords

Atopic dermatitis; Eczema; Elidel; Flare prevention; Long term management; Pimecrolimus cream 1

Indexed keywords

CORTICOSTEROID; DIFLUPREDNATE; FLUTICASONE PROPIONATE; HYDROCORTISONE; HYDROCORTISONE BUTYRATE; MOMETASONE FUROATE; PIMECROLIMUS; PREDNICARBATE;

ADOLESCENT; APPLICATION SITE BURNING; ARTICLE; ASTHMA; ATOPIC DERMATITIS; BRONCHITIS; CHICKENPOX; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEVER; FLU LIKE SYNDROME; FOLLOW UP; GASTROENTERITIS; HEADACHE; HUMAN; IMPETIGO; INFLUENZA; MAJOR CLINICAL STUDY; MALE; MOLLUSCUM CONTAGIOSUM; MULTICENTER STUDY; OTITIS MEDIA; PHARYNGITIS; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RHINITIS; RHINOPHARYNGITIS; SCHOOL CHILD; SORE THROAT; STREPTOCOCCUS INFECTION; TONSILLITIS; UPPER RESPIRATORY TRACT INFECTION; URTICARIA; VIRAL GASTROENTERITIS; VOMITING;

ADMINISTRATION, TOPICAL; ADOLESCENT; CHILD; CHILD, PRESCHOOL; DERMATITIS, ATOPIC; DERMATOLOGIC AGENTS; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; HUMANS; TACROLIMUS; TREATMENT OUTCOME;

EID: 53749087560     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2008.02785.x     Document Type: Article

References (63)

1. Leung DYM, Bieber T. Atopic dermatitis. Lancet 2003 361 : 151 160.
2. Kemp AS. Cost of illness of atopic dermatitis in children: a societal perspective. Pharmacoeconomics 2003 21 : 105 113.
3. Su JC, Kemp AS, Varigos GA, Nolan TM. Atopic eczema: its impact on the family and financial cost. Arch Dis Child 1997 76 : 159 162.
4. Elliot BE, Luker K. The experience of mothers caring for a child with severe atopic eczema. J Clin Nurs 1997 6 : 241 247.
5. Pauli-Pott U, Darui A, Beckmann D. Infants with atopic eczema: maternal hopelessness, child-rearing attitudes and perceived infant temperament. Psychother Psychosom 1999 68 : 39 45.
6. Finlay AY. Quality of life in atopic dermatitis. J Am Acad Dermatol 2001 45 : S64 S66.
7. Przybilla B, Eberlein-Konig B, Rueff F. Practical management of atopic eczema. Lancet 1994 343 : 1342 1346.
8. Williams HC. Do topical steroids reduce relapses in adults with atopic dermatitis? Arch Dermatol 1999 135 : 1530 1531.
9. Leung DYM, Boguniewicz M, Howell MD, Nomura I, Hamid QA. New insights into atopic dermatitis. J Clin Invest 2004 113 : 651 657.
10. Leung DYM. Atopic dermatitis: new insights and opportunities for therapeutic intervention. J Allergy Clin Immunol 2000 105 : 860 876.
11. Boguniewicz M, Eichenfield LF, Hultsch T. Current management of atopic dermatitis and interruption of the atopic march. J Allergy Clin Immunol 2003 112 : S140 S150.
12. Hoare C, Li Wan Po A, Williams H. Systematic review of treatments of atopic eczema. Health Technol Assess 2000 4 : 1 191.
13. Hanifin JM, Cooper KD, Ho VC et al. Guidelines of care for atopic dermatitis. J Am Acad Dermatol 2004 50 : 391 404.
14. Raimer SS. Managing pediatric atopic dermatitis. Clin Pediatr 2000 39 : 1 14.
15. Wolkerstorfer A, Strobos MA, Glazenburg EJ et al. Fluticasone proprionate 0.05% cream once daily versus clobetasone butyrate 0.05% cream twice daily in children with atopic dermatitis. J Am Acad Dermatol 1998 39 : 226 231.
16. Luger TA, Lahfa M, Fölster-Holst R et al. Long-term safety and tolerability of pimecrolimus cream 1% and topical corticosteroids in adults with moderate to severe atopic dermatitis. J Dermatolog Treat 2004 15 : 169 178.
17. Hill CJ, Rosenberg A Jr. Adverse effects from topical corticosteroids. Cutis 1978 21 : 624 628.
18. Stoppolino G, Prisco F, Santinelli R, Sicuranza G, Giordano C. Potential hazards of topical steroid therapy. Am J Dis Child 1983 137 : 1130 1131.
19. Lewis-Jones S. Atopic dermatitis in childhood. Hosp Med 2001 62 : 136 143.
20. Queille C, Pommarede R, Saurat JH. Efficacy versus systemic side effects of six topical steroids in the treatment of atopic dermatitis of childhood. Pediatr Dermatol 1984 1 : 246 253.
21. Turpeinen M, Salo OP, Leisti S. Effect of percutaneous absorption of hydrocortisone on adrenocortical responsiveness in infants with severe skin disease. Br J Dermatol 1986 115 : 475 484.
22. Turpeinem M. Influence of age and severity of dermatitis on the percutaneous absorption of hydrocortisone in children. Br J Dermatol 1988 118 : 517 522.
23. Turpeinen M, Lehtokoski-Lehtiniemi E, Leisti S, Salo OP. Percutaneous absorption of hydrocortisone during and after the acute phase of dermatitis in children. Pediatr Dermatol 1988 5 : 276 279.
24. Queille-Roussel C, Paul C, Duteil C et al. The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double blind controlled study. Br J Dermatol 2001 144 : 507 513.
25. Haapasaari KM, Risteli J, Koivukangas V, Oikarinen A. Comparison of the effect of hydrocortisone, hydrocortisone-17-butyrate and betamethasone on collagen synthesis in human skin in vivo. Acta Derm Venereol 1995 75 : 269 271.
26. Haapasaari KM, Risteli J, Karvonen J, Oikarinen A. Effect of hydrocortisone, methylprednisolone acetonate and mometasone furoate on collagen synthesis in human skin in vivo. Skin Pharmacol 1997 10 : 261 264.
27. Oikarinen A, Haapasaari KM, Sutinen M, Tasanen K. The molecular basis of glucocorticoid-induced skin atrophy: topical glucocorticoid apparently decreases both collagen synthesis and the corresponding collagen mRNA level in human skin in vivo. Br J Dermatol 1998 139 : 1106 1110.
28. Sheu HM, Lee JYY, Chai CY, Kuo K. Depletion of stratum corneum intercellular lipid lamellae and barrier function abnormalities after long-term topical corticosteroids. Br J Dermatol 1997 136 : 884 890.
29. Kolbe L, Kligman AM, Schreiner V, Stoudemayer T. Corticosteroid-induced atrophy and barrier impairment measured by non-invasive methods in human skin. Skin Res Technol 2001 7 : 73 77.
30. Kao JS, Fluhr JW, Man MQ et al. Short-term glucocorticoid treatment compromises both permeability barrier homeostasis and stratum corneum integrity: inhibition of epidermal lipid synthesis accounts for functional abnormalities. J Invest Dermatol 2003 120 : 456 464.
31. Hengge UR, Ruzicka T, Schwartz RA, Cork MJ. Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol 2006 54 : 1 15.
32. du Vivier A. Tachyphylaxis to topically applied steroids. Arch Dermatol 1976 112 : 1245 1248.
33. Kligman AM, Frosch PJ. Steroid addiction. Int J Dermatol 1979 18 : 23 31.
34. Zheng PS, Lavker RM, Lehmann P et al. Morphologic investigations on the rebound phenomenon after corticosteroid-induced atrophy in human skin. J Invest Dermatol 1984 82 : 345 352.
35. Singh G, Singh PK. Tachyphylaxis to topical steroids measured by histamine-induced wheal suppression. Int J Dermatol 1986 25 : 324 326.
36. Fischer G. Compliance problems in pediatric atopic eczema. Aust J Dermatol 1996 37 : 10 13.
37. Charman CR, Morris AD, Williams HC. Topical corticosteroid phobia in patients with atopic eczema. Br J Dermatol 2000 142 : 931 936.
38. Fukaya M. Why do patients with atopic dermatitis refuse to apply topical corticosteroids? Dermatology 2000 201 : 242 245.
39. Graham-Brown RAC, Grassberger M. Pimecrolimus: a review of preclinical and clinical data. Int J Clin Pract 2003 57 : 319 327.
40. Grassberger M, Steinhoff M, Schneider D, Luger TA. Pimecrolimus - an anti-inflammatory drug targeting the skin. Exp Dermatol 2004 13 : 721 730.
41. Eichenfield LF, Lucky AW, Boguniewicz M et al. Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J Am Acad Dermatol 2002 46 : 495 504.
42. Meurer M, Folster-Holst R, Wozel G, Weidinger G, Jungerf M, Brautigam M. Pimecrolimus cream in the long-term management of atopic dermatitis in adults: a six-month study. Dermatology 2002 205 : 271 277.
43. Kapp A, Papp K, Bingham A et al. Flare Reduction in Eczema with Elidel (infants) multicentre investigator study group: long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug. J Allergy Clin Immunol 2002 110 : 277 284.
44. Wahn U, Bos JD, Goodfield M et al. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics 2002 110 : e2.
45. McKenna S, Whalley D, de Prost Y et al. Treatment of paediatric atopic dermatitis with pimecrolimus (Elidel®, SDZ ASM 981): impact on quality of life and health-related quality of life. J Eur Acad Dermatol Venereol 2006 20 : 248 254.
46. Ho VC, Gupta A, Kaufmann R et al. Safety and efficacy of nonsteroid pimecrolimus cream 1% in the treatment of atopic dermatitis in infants. J Pediatr 2003 142 : 155 162.
47. Kaufmann R, Folster-Holst R, Hoger P et al. Onset of action of pimecrolimus cream 1% in the treatment of atopic eczema in infants. J Allergy Clin Immunol 2004 114 : 1183 1188.
48. Papp KA, Werfel T, Fölster-Holst R et al. Long-term control of atopic dermatitis with pimecrolimus cream 1% in infants and young children: a two-year study. J Am Acad Dermatol 2005 52 : 240 246.
49. Harper J, Green A, Scott G et al. First experience of topical SDZ ASM 981 in children with atopic dermatitis. Br J Dermatol 2001 144 : 781 787.
50. Harper J, Lakhanpaul M, Wahn U et al. Pimecrolimus (Elidel®, SDZ ASM 981) cream 1% blood levels are consistently low in children with extensive atopic dermatitis. J Eur Acad Dermatol Venereol 2001 15 (Suppl. 2 abstract 109 110.
51. Lakhanpaul M, Davies T, Allen BR, Schneider D. Low systemic exposure in infants with atopic dermatitis in a 1-year pharmacokinetic study with pimecrolimus cream 1%. Exp Dermatol 2006 15 : 138 141.
52. Allen BR, Lakhanpaul M, Morris A et al. Systemic exposure, tolerability, and efficacy of pimecrolimus cream 1% in atopic dermatitis patients. Arch Dis Child 2003 88 : 969 973.
53. Papp KA, Breuer K, Meurer M et al. Long-term treatment of atopic dermatitis with pimecrolimus cream 1% in infants does not interfere with the development of protective antibodies after vaccination. J Am Acad Dermatol 2005 52 : 247 253.
54. Hultsch T, Kapp A, Spergel J. Immunomodulation and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis. Dermatology 2005 211 : 174 187.
55. Food Drug Administration: FDA News. FDA approves updated labeling with box warning and medication guide for two eczema drugs, Elidel and Protopic. [WWW document] 2006. URL http://www.fda.gov/bbs/topics/news/ 2006/NEW01299.html (last accessed: 30 April 2008).
56. Kaplan EL, Meier P. Non-parametric estimation from incomplete samples. J Am Stat Assoc 1958 36 : 457 481.
57. Prentice RL, Williams BJ, Petersen AV. On the regression of multivariate failure time data. Biometrika 1981 68 : 373 379.
58. Eichenfield LF, Lucky AW, Langley RGB et al. Use of pimecrolimus cream 1% (Elidel®) in the treatment of atopic dermatitis in infants and children: the effects of ethnic origin and baseline disease severity on treatment outcome. Int J Dermatol 2005 44 : 70 75.
59. Gould AL. A new approach to the analysis of clinical drug trials with withdrawals. Biometrics 1980 36 : 721 727.
60. Conover WJ, Iman RL. Rank transformations as a bridge between parametric and nonparametric statistics (with discussion). Am Stat 1981 35 : 124 133.
61. Noether GE. Sample size determination for some common nonparametric tests. J Am Stat Assoc 1987 82 : 645 647.
62. Paul C, Cork MJ, Rossi AB, Papp KA, Barbier N, de Prost Y. Safety and tolerability of 1% pimecrolimus cream among infants: experience with 1133 patients treated for up to 2 years. Pediatrics 2006 117 : e118 e128.
63. Gollnick H, Kaufmann R, Stough D et al. Pimecrolimus cream 1% in the long-term management of adult atopic dermatitis: prevention of flare progression. A randomized controlled trial. Br J Dermatol 2008 158 : 1083 1093.